All News
Random Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes
Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients.
Read ArticleRituximab May Reduce Mortality Risk in Rheumatoid Lung Disease
While it is known that rheumatoid arthritis (RA) patients with interstitial lung involvement is associated with severe seropositive disease and is associated with an increased mortality.
Read ArticleNonsignificant CV Risk with Actemra vs Enbrel
WASHINGTON -- Rheumatoid arthritis is a recognized risk factor for heart attacks and stroke, but a study comparing two leading biologics found only a non-significant increase in relative risk for patients treated with toclizimab (Actemra) vs etanercept (Enbrel), researchers reported here.
Read ArticlePhysicians Still Over-Prescribe Antibiotics, Narcotics and Opioids
A study by the American College of Physicians (ACP) found that physicians continue to prescribe treatments that offer little benefit to patients, despite the advice of clinical guidelines.
Read ArticleKey Lessons from the TNF Inhibitor Head-to-Head EXXELERATE Study
The EXXELERATE study is featured prominently in Lancet this week. In some ways, this represents a landmark negative trial that rheumatologists should review and be aware of.
Read ArticleIs ABT-494 the Next JAK Inhibitor?
Tofacitinib may well be joined by a new once daily JAK inhibitor, baricitinib in the next few months.
Read ArticleThe RheumNow Week in Review – 2 December 2016
Dr. Cush highlights reports from this week on RheumNow.com.
Read ArticleCURES Act : House Passes Largest Bill Since Obamacare
The 21st Century Cures Act has become one of the most-lobbied health care bills in recent history, with nearly a half billion dollars being spent on both sides - those for and against the bill.
Read ArticleASDAS Activity Correlates with Xray Progression in Spondyloarthritis
Investigators analyzed a prospective study of patients with early axial spondyloarthritis (axSpA) to assess predictors of outcome.
Read ArticleUstekinumab Effective and Safe in Crohn's Colitis
The New England Journal of Medicine has reported the results of a large clinical trial demonstrating the efficacy of ustekinumab (Stelara) in treating patients with active Crohn's disease (CD). (Citation source http://buff.ly/2gsSNcs)
Read ArticleMaintenance of Remission in ANCA-vasculitis: MAINRITSAN study.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Read ArticleThree Year Data on Secukinumab
Dr. Philip Mease, MD presented the long-term efficacy and safety data for secukinumab in psoriatic arthritis (PsA) at the ACR Annual meeting in Washington, DC.
Read ArticleACR16 Day 4 Ends with Rheumatology Roundup
The final day of the 2016 annual ACR meeting saw the return of "Rheumatology Round-up" at 7:30am in Hall D.
Read ArticleACR 2016 – Day 3 Highlights
Some big highlights from Tuesday at the 2016 ACR/ARHP annual meeting included the PRECISION trial, EXXELERATE trial and the new anti-IL-23 in psoriatic arthritis.
Read ArticleCelecoxib Shines and Naproxen Tanks in the PRECISION Study
The PRECISION trial was published this week in the NEJM, presented at the Cardiology meetings in New Orleans, and presented today by Dr. Daniel Solomon at the 2016 ACR annual meeting in Washington, D.C. (citation source http://buff.ly/2fUmoqO)
Read ArticleACR 2016 – Day 2 Highlights
Big highlights from Monday included the Hench Lecture, plenary session abstracts and presentations on drug safety and cost efficacy in rheumatoid arthritis.
Read ArticleMaintenance of Remission in ANCA-vasculitis: MAINRITSAN study.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Read ArticleCORRONA Presentations at ACR 2016
CORRONA, America's largest registry, has numerous presentations for this year's annual ACR/ARHP meeting. See below for the expanse of efficacy and safety issues covered by CORRONA investigators.
Read ArticleTwo New Biologics for Polyarticular JIA
On Monday, November 13, there were two new presentations at the annual ACR 2016 meeting on new biologics seeking approval for use in polyarticular juvenile arthritis.
Read Article